Liu lng: Ung ngy 2 vin/ngy, chia 2 ln vo bui sng v bui ti
Randomized controlled trials that substitute UPFs with minimally processed or whole-food dietary patterns, such as the Mediterranean diet, could be useful in providing stronger therapeutic evidence by assessing the extent to which dietary modification may reduce the severity and/or mitigate the types of psychiatric presentations
What the evidence supports: Injectable semaglutide was undetectable in breast milk from eight nursing mothers at doses up to 1 mg weekly Injectable tirzepatide was undetectable in approximately 96 percent of milk samples from 11 nursing mothers at 5 mg doses Both medications have molecular weights (4,114 and 4,813 Daltons) that make significant milk transfer biologically unlikely Any trace amounts in milk would have negligible oral bioavailability in the infant No adverse infant effects were observed in any of the lactation studies LactMed states tirzepatide is not a reason to discontinue breastfeeding What the evidence does not support: Use of oral semaglutide (Rybelsus) during breastfeeding due to the absorption enhancer SNAC Use of any GLP-1 agonist without physician supervision during lactation Aggressive weight loss goals (more than 1 to 1.5 pounds per week) while breastfeeding Assumption that compounded formulations carry the same safety profile as pharmaceutical-grade products without specific data What remains unknown: Safety at higher therapeutic doses (semaglutide above 1 mg, tirzepatide above 5 mg) Long-term infant outcomes from maternal GLP-1 exposure during breastfeeding Effects on breast milk composition and nutritional quality Safety of newer GLP-1 agonists like retatrutide The decision is ultimately yours and your physician's
[28] Additionally, a randomized control trial study by Maruyama and colleagues, illustrated that carnitine supplementation helps maintain muscle mass and strength, specifically in individuals undergoing hemodialysis, as well as in those with diabetes and the elderly
